Eye exams may soon serve a larger purpose than detecting vision changes. Because the retina is an extension of the brain and shares many similarities with the brain, researchers believe that the deterioration in the retina may mirror the changes going on in the blood vessels in the brain, thereby offering a window into the […]
Google has created a new Android app to help the visually impaired. Similar to Microsoft’s Seeing AI for Apple devices, the application, named Lookout, uses artificial intelligence (AI) to identify objects, read text, scan barcodes, and identify currencies. It is available to download though only for Google’s Pixel devices in the U.S. at this time. It is not clear […]
Researchers at the University of Oxford have carried out the world’s first gene therapy operation to tackle the root cause of age-related macular degeneration (AMD). An 80-year-old woman with AMD is the first of ten people to receive the treatment. The procedure was carried out at the John Radcliffe Hospital by Professor Robert MacLaren, Professor […]
by Dan Roberts Artificial intelligence (AI) makes it possible for machines to learn from experience, adjust to new inputs, and perform human-like tasks. It provides us with human-like interactions with computers and helps us with difficult decision making. AI works by super-speed processing of large amounts of information (data), allowing the software to learn automatically […]
With recent successes in gene replacement therapy, scientists are enthused about studying how genetic variants play a part in age-related macular degeneration (AMD). Previous research has identified 34 small genomic regions (“loci”) on the DNA molecule and 52 genetic variants (mutations) within those loci that are associated with AMD. Variants can regulate certain genes to […]
New Website offers Patients Comprehensive, Educational Resources to Navigate Life with Age-Related Macular Degeneration Bausch + Lomb, a leading global eye health company, has announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD […]
Three anti-VEGF drugs are in clinical use for treatment of wet age-related macular degeneration (wAMD). These are Lucentis (ranibizumab), off-label Avastin (bevacizumab), and Eylea (ranibizumab). The rate of stroke from intravitreal injections of Lucentis was found in the early clinical trials to be 0.2% (1 of 525) in the combined group of patients compared to […]
A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD). Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose […]
Your story can help the Prevent Blindness organization improve vision treatment. Has your eye doctor prescribed a medication or a treatment to address your eye health condition? If so, have you ever found that your insurance company requires you to first try a generally cheaper and possibly less effective drug before they will approve the one […]
New research published this week in Clinical Epigenetics, has identified two new genes linked to the development of age-related macular degeneration (AMD). Led by Dr. Louise Porter at the University of Liverpool, the team identified genes that may become new targets for treatments. 44 human donor eyes were profiled for levels of DNA methylation (a […]